Podcasts about Hypertrophic cardiomyopathy

Join Tales From the Heart host Lisa Salberg for an easy to understand discussion about Hypertrophic Cardiomyopathy with Dr. Matt Martinez.   This conversation was recorded March 7, 2025.

Tales From the Heart host Lisa Salberg introduces us to Algenis Romero. Algenis shares his story of when he learned he Hypertrophic Cardiomyopathy and how he decided to become an advocate for HCMA.   This conversation was recorded Feb. 28, 2025.

In this second entry in the JACC-Baran Japanese language series, JACC Executive Associate Editor Mitsuaki Sawano, MD, Shun Kohsaka, MD, FACC, and Yuichi Shimada, MD, MPH, speak on topics ranging from all things Super Bowl to Dr. Shimada's recently published JACC paper, Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.

Host: Darryl S. Chutka, M.D. Guest: Jeffrey B. Geske, M.D. Hypertrophic cardiomyopathy affects 1 in 500 adults or about 600,000 individuals in the U.S. and represents the most common inherited cardiomyopathy.  It often goes undetected, and it's estimated that about 85% of those with the condition remain undiagnosed. HCM can produce a variety of symptoms, the most serious being sudden death. The topic for this podcast is Hypertrophic Cardiomyopathy.  What are the clues that might make us suspect a patient has HCM and how should we confirm the diagnosis? Are we able to prevent sudden death in patients with the condition and finally, what is the most effective treatment? I'll asking these questions of my guest, Jeffrey B. Geske, M.D., from the Department of Cardiovascular Diseases at Mayo Clinic. For more information on heart health, check out Mayo Clinic Talks: Heart Health | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Watch our panel of experts and get up to speed on hypertrophic cardiomyopathy (HCM) through a series of quickfire questions and teaching points. Credit available for this activity expires: 01/31/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/new-paradigms-hypertrophic-cardiomyopathy-care-gameshow-2025a10002f4?ecd=bdc_podcast_libsyn_mscpedu

Welcome to Tales from the Heart! This week host Lisa Salberg sits down with Dr. Wojciech Mazur who is a Hypertrophic Cardiomyopathy physician and patient. Listen to his interesting perspective and thoughts about the disease as we move into 2025.   The conversation was recorded Jan. 17, 20245

In this episode, we review the high-yield topic ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hypertrophic Cardiomyopathy ⁠⁠⁠⁠⁠⁠⁠⁠from the Cardiovascular section at ⁠⁠⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠ Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Hypertrophic cardiomyopathy (or HCM for short) is a serious heart condition that involves thickening of the heart muscle wall and disruption of the normal tissue architecture, called ‘disarray'. This can result in sudden cardiac death caused by abnormal heart rhythms, known as arrhythmias. Identifying those HCM patients who are most at risk could permit preventative measures, such as implanting a cardioverter-defibrillator, which could potentially be lifesaving. However, current techniques to predict the risk of sudden death in HCM are limited, leaving patients underserved. In a recent study, Dr Richard Saumarez, an academic cardiologist formerly of the University of Cambridge, and colleagues, questioned whether conventional methods, which consider risk factors such as family history of sudden death or the degree of heart muscle thickening, are effective in predicting sudden death in HCM patients. Their research suggests that risk factor assessments might miss crucial information about the heart's electrical behaviour, which could provide more accurate clues about the risk of sudden death. As an alternative, the researchers propose direct heart-investigation methods, called electrophysiological techniques, as a more reliable assessment. Although the study was concerned with HCM, the arguments put forward are more general and applicable to other diseases, particularly to survivors of myocardial infarcts who are also at risk of sudden death.

On this episode of "Tales From the Heart" host Lisa Salberg is joined by Prof. Perry Elliott for a discussion about the future of Hypertrophic Cardiomyopathy.   This conversation was recorded Dec. 13, 2024.

CardioNerds (Dr. Dan Ambinder and guest host, Dr. Pooja Prasad) join Dr. Donny Mattia from Phoenix Children's pediatric cardiology fellowship, Dr. Sri Nayak from the Mayo Clinic – Arizona adult cardiology fellowship, and Dr. Harrison VanDolah from the University of Arizona College of Medicine - Phoenix Med/Peds program for a sunrise hike of Piestewa Peak, followed by some coffee at Berdena's in Old Town Scottsdale (before the bachelorette parties arrive), then finally a stroll through the Phoenix Desert Botanical Gardens to discuss a thought-provoking case series full of clinical cardiology pearls. Expert commentary is provided by Dr. Tabitha Moe. Episode audio was edited by Dan Ambinder. They discuss the following case: Cardiology is consulted by the OB team for a 27-year-old female G1, now P1, who has just delivered a healthy baby boy at 34 weeks gestation after going into premature labor. She is experiencing shortness of breath and is found to have a significant past cardiac history, including atrial fibrillation and preexcitation, now with a pacemaker and intracardiac defibrillator. We review the differential diagnosis for peripartum cardiomyopathy (PPCM) and then combine findings from her infant son, who is seen by our pediatric cardiology colleagues and is found to have severe hypertrophic cardiomyopathy (HCM). Genetic testing for both ultimately reveals a LAMP2 mutation consistent with Danon Disease. The case discussion focuses on the differential diagnosis for PPCM, HCM, pearls on Danon Disease and other HCM “phenocopies,” and the importance of good history. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media Pearls Peripartum cardiomyopathy is a diagnosis of exclusion – we must exclude other possible etiologies of heart failure! Be on the lookout for features of non-sarcomeric HCM – as Dr. Michelle Kittleson said in Episode 166, “LVH plus” states. HCM with preexcitation, heart block, strong family history, or extracardiac symptoms such as peripheral neuropathy, myopathy, or cognitive impairment should be evaluated for infiltrative/inherited cardiomyopathies! As an X-linked dominant disorder, Danon disease will present differently in males vs females, with males having much more severe and earlier onset disease with extracardiac features. Making the diagnosis for genetic disorders such as Danon disease is important for getting the rest of family members tested as well as the opportunity for specialized treatments such as gene therapy Up to 5% of Danon disease cases may be due to copy number variants, which may be missed in genetic testing that does not do targeted deletion/duplication analysis!). Notes What is the differential diagnosis for peripartum cardiomyopathy? Peripartum cardiomyopathy is a diagnosis of exclusion – we must exclude other possible etiologies of heart failure! First, ensure that you are not missing an acute life-threatening etiology of acute decompensated heart failure – pulmonary embolism, amniotic fluid embolism, ACS, and SCAD should all be ruled out. Second, a careful history can identify underlying heart disease or risk factors for the development of heart failure, such as substance use, high-risk behaviors that put one at risk for HIV infection, and family history that suggests an inheritable cardiomyopathy. Lastly, a careful review of echocardiographic imaging may also identify underlying etiologies that warrant a change in management. Diagnosis of peripartum cardiomyopathy is important to consider as within 7 days of onset, patients may be eligible for treatment with bromocriptine – consider referring ...

In this episode, Dr. Valentin Fuster discusses groundbreaking research on hypertrophic cardiomyopathy (HCM), revealing dysregulated signaling pathways through comprehensive proteomic profiling of human myocardial tissue. The study identifies novel therapeutic targets, including the Ras MAPK pathway and the ubiquitin-proteasome system, while emphasizing the need for further exploration beyond obstructive cases to better understand the disease's molecular mechanisms.

In this episode, Dr. Valentin Fuster dives into a pivotal study on hypertrophic cardiomyopathy, focusing on the challenges of identifying at-risk relatives when genetic variants are not found in 60% of families. With insights into the disease's autosomal dominant inheritance and incomplete penetrance, this discussion highlights the complexities of family screening and the need for innovative approaches in managing this condition.

In this episode, Dr. Valentin Fuster highlights the Forest HCM study, which focuses on the withdrawal of standard care medications in patients with obstructive hypertrophic cardiomyopathy receiving afficantin. The study shows promising results: nearly half of the patients who attempted to reduce or stop their medications did so successfully, with significant improvements in functional class and symptoms. While the findings suggest that afficantin may allow for the reduction of traditional therapies, caution is advised, as not all patients may benefit equally.

In this episode, Dr. Valentin Fuster introduces a dedicated focus on hypertrophic cardiomyopathy, featuring a pivotal study by Dr. Martin Maron and Dr. lacopo Olivotto on the impact of aficamptin. This pre-specified sub-analysis from the SEQUOIA HCM trial aims to comprehensively evaluate the drug's effects on various aspects of disease burden, enhancing our understanding of its clinical efficacy.

In this episode, Dr. Valentin Fuster delves into a groundbreaking study on the effects of the cardiac myosin inhibitor, Aficamten, on patients with obstructive hypertrophic cardiomyopathy. The findings reveal significant improvements in echocardiographic measures of cardiac function, despite a mild and reversible decrease in left ventricular ejection fraction, highlighting the need for long-term safety evaluations of this promising treatment.

In this episode, Dr. Valentin Fuster explores groundbreaking research on hypertrophic cardiomyopathy, focusing on the effects of the drug aficamten on cardiac structure and function. Highlighting significant findings from the Sequoia HCM trial, the discussion underscores the potential of aficamten to induce favorable cardiac remodeling and improve patient outcomes, signaling a transformative era in the management of this condition.

In this episode, Dr. Valentin Fuster delves into the latest research on hypertrophic cardiomyopathy, highlighting the significant health status improvements achieved with the new cardiac myosin inhibitor, Aficamten, compared to placebo. The findings from the Sequoia HCM study reveal that Aficamten markedly enhances patients' quality of life and alleviates symptoms like chest pain and shortness of breath, paving the way for more effective treatments in this challenging condition.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on long-term outcomes of patients with apical hypertrophic cardiomyopathy utilizing a new risk score.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on clinical course and treatment of patients with apical aneurysms due to hypertrophic cardiomyopathy.

Discover how a near-death ischemic stroke caused by hypertrophic cardiomyopathy led to an extraordinary recovery journey filled with resilience. The post Surviving an Ischemic Stroke: Roderick Jefferson's Journey with Hypertrophic Cardiomyopathy and Recovery appeared first on Recovery After Stroke.

This episode contains: Your usual hosts are back at it again, diving into personal updates and some wild topics! Ben is at capacity, juggling directing and editing a school fundraiser ad. Meanwhile, Steven is busy dog-sitting and catching up on Agatha All Along and The Penguin. Ben also shares that his old cat has been diagnosed with Hypertrophic Cardiomyopathy. Devon, well, he's keeping quiet this week. The Ultimate Slap Bet: Steven introduces us to the world of slap fighting! We discuss the rise of slap competitions and how it ties into this recent scientific study and the rules from the Power Slap League. Plus, a quick throwback to the chaotic days of Jackass—because who can forget? PS5 Nostalgia: Ben takes us on a trip down memory lane with the PlayStation exclusive Astro Bot. It's a love letter to 30 years of PlayStation history, and you can check it out here. Book Club: We're prepping for next week's read, The Remedy from the Dark Corners collection. But first, let's talk mini-golf! We review the new Walkabout Mini Golf Mars course and its unique sci-fi theme. From eerie, isolated landscapes to hints of past civilizations, it's inspired by the 1972 classic Silent Running. You can read more about the course here. Dungeon Crawler Carl: Devon is loving Dungeon Crawler Carl, while Steven's love for the book is still going strong. Ben hasn't had the chance to dive back into it yet, but we'll keep him in the loop! That's it for this week! Don't forget to grab a copy of The Remedy for next week's book club discussion.

George Cooper is joined by Perry Elliott, Professor of Cardiovascular Medicine at University College London, UK, and Anjali Owens, Associate Professor of Medicine in the Division of Cardiology at the Perelman School of Medicine of the University of Pennsylvania, USA. Following an incredible symposium session at the 2024 European Society of Cardiology (ESC) Congress, they discuss case studies and real-world evidence relating to hypertrophic cardiomyopathy and the use of mavacamten.

Hey Heart Buddies! We hear from Holly Morrell who shares the profound impact of hypertrophic cardiomyopathy on her family and herself including her personal experience with a faulty defibrillator implant, multiple surgeries, and a life-threatening rupture that necessitated open-heart surgery. Despite these challenges, Holly finds strength and purpose, continually striving to prevent sudden cardiac arrest in communities through her nonprofit, Heartfelt. You can get in touch with her at holly@heartfeltscreening.orgJoin the Patreon Community! The Heart Chamber zoom group starts in September 2024.**I am not a doctor and this is not medical advice. Be sure to check in with your care team about all the next right steps for you and your heart.**How to connect with BootsEmail: Boots@theheartchamberpodcast.comInstagram: @openheartsurgerywithboots or @boots.knightonLinkedIn: linkedin.com/in/boots-knightonBoots KnightonIf you enjoyed this episode, take a minute and share it with someone you know who will find value in it as well. You can share directly from this platform or send them to:Open Heart Surgery with Boots

Not all tackles happen on the field. Che Morales, once on the brink of a promising CFL career, found his life upended by a surprising diagnosis. What started as shortness of breath, initially thought to be COVID, led to the shocking discovery of Hypertrophic Cardiomyopathy (HCM). This episode delves into Che's journey from being a university football powerhouse to grappling with a condition that thickens the walls of the heart's left ventricle, ending his athletic dreams. As Che navigates this unexpected life shift, he shares his struggles and hopes, exploring what it means to redefine oneself when the playbook changes dramatically. Tune in for the wrap up as the fellas talk about a hail mary that Tokoyo is throwing to try and get more babies made before it's too late. Catch the full video version of this episode on YouTube! Follow Sickboy on Instagram, TikTok and Discord

FREE! CRNA School Interview Prep Guide: https://www.cspaedu.com/uc9a5ih4Join us for a riveting session on hypertrophic cardiomyopathy (HCM) led by the esteemed CRNA, Shannon Pecka! As the Assistant Program Director at Bryan College of Health Sciences, Shannon Pecka brings a wealth of knowledge and experience to the table. In this informative session, Shannon will delve deep into the intricacies of HCM, equipping you with a comprehensive understanding of this most common inherited cardiac abnormality. She explains how to manage potential complications associated with HCM. Shannon also shares strategies to optimize anesthesia care for HCM patients. Don't miss this opportunity to learn from the best! This episode is an invaluable resource for CRNAs, anesthesiologists, and healthcare professionals seeking to refine their knowledge of hypertrophic cardiomyopathy and its management.Learn More about the Bryan College of Health Sciences DNAP Program: https://www.bryanhealthcollege.edu/bcohs/academic-programs/nurse-anesthesia/Get access to planning tools, interview preparation opportunities, valuable CRNA Faculty guidance, and mapped-out courses that have been proven to accelerate your CRNA success! Become a member of CRNA School Prep Academy: https://cspaedu.com/joinFast-Track Your CRNA Interview Prep with our CRNA Interview Crash Course! https://www.cspaedu.com/4wotmldsHave you gained acceptance to CRNA school? Congratulations! Prepare with the #1 pre-anesthesia curriculum, as recommended by CRNA program faculty. Start the NAR Boot Camp today: https://www.cspaedu.com/bootcampGet CRNA School insights sent straight to your inbox! Join the CSPA email list: https://www.cspaedu.com/podcast-emailJoin the Free Facebook Community here! https://www.facebook.com/groups/crnaschoolprepacademyfreeBook a mock interview, resume or personal statement critique, transcript review and more: www.teachrn.com

Not all tackles happen on the field. Che Morales, once on the brink of a promising CFL career, found his life upended by a surprising diagnosis. What started as shortness of breath, initially thought to be COVID, led to the shocking discovery of Hypertrophic Cardiomyopathy (HCM). This episode delves into Che's journey from being a university football powerhouse to grappling with a condition that thickens the walls of the heart's left ventricle, ending his athletic dreams. As Che navigates this unexpected life shift, he shares his struggles and hopes, exploring what it means to redefine oneself when the playbook changes dramatically. Tune in for the wrap up as the fellas talk about a hail mary that Tokoyo is throwing to try and get more babies made before it's too late. Catch the full video version of this episode on YouTube! Follow Sickboy on Instagram, TikTok and Discord

Join Michelle Michels, Head of the Centre of Expertise for Inherited Cardiovascular Disease, Erasmus University Medical Centre, Rotterdam, the Netherlands, for the latest episode of the EMJ Podcast.   A summary of the pathophysiology and clinical manifestations of HCM is presented, followed by a discussion on the challenges in managing HCM, the correlations between genotype and phenotype, and significant advancements derived from the analysis of long-term extension data.   Listen now for more insights into this fascinating subject!

Commentary by Dr. Valentin Fuster

In this On Demand video, Dr. Steve Ommen and Dr. Carolyn Ho discuss recent updates to the 2024 Guideline for the Management of Hypertrophic Cardiomyopathy (HCM). Watch now to enhance your knowledge on the importance of shared decision-making, the use of cardiac myosin inhibitors to treat symptomatic obstructive HCM, and risk stratification for atrial fibrillation to improve patient outcomes.

Commentary by Dr. Emile Daoud

Commentary by Dr. Candice Silversides

Commentary by Dr. Valentin Fuster

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DMR865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DMR865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DMR865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

In this episode, Tracy shares her journey from a young girl diagnosed with Hypertrophic Cardiomyopathy to adulthood finding out thanks to her husband that she was in heart failure and would need a to have a heart transplant.It wasn't until her early 40's that doctors told her that her conditioned had worsened and that she need to stop all physical activity.  Tracy was put on a heart transplant list and began the long process of finding a donor match despite what she was told were very low odds. Then to everyone's surprise Tracy got a call from Cedars-Sinai in LA saying they were going ahead with a transplant.  On May 31st, 2020 Tracy was gifted a second chance at life from her heart donor Rick ❤️#hypertrophiccardiomyopathy #hcm #hearttransplant #hearttransplantrecipient #hearttransplantsurvivor #donormatch #beattheodds #powerfulstory #healingthroughthepowerofstorytelling #cedarssinaitransplantteam #familyhistory #father #son #fighter #groundedingratitude #heartattackthriver #theheartattackthriver #theheartattackthriverpodcastPodcast Disclaimer:The information and opinions presented in the Heart Attack Thriver Podcast is not intended as, and shall not be understood or construed as, medical advice. While the information provided on this Podcast relates to medical issues, and health and wellness, the information is not a substitute for medical advice from a Medical Professional who is aware of the facts and circumstances of your individual situation.Thank you for listening and please be sure to hit “SUBSCRIBE”, and “SHARE” this podcast with anyone that you feel could benefit from it.If you'd like to reach me for support or to leave a comment or feedback, please send an email to:: brian@thekindfulnesscoach.com

Welcome to Tales from the Heart's patient journey segment: Share Your Story. Host Lisa Salberg introduces us to Lekeshia Henderson. She lost her brother to HCM which led her to the discovery that she too has Hypertrophic Cardiomyopathy. This conversation was recorded Apr. 26, 2024.

Commentary by Dr Milind Desai

The Hypertrophic Cardiomyopathy Association (HCMA) is a leading organization dedicated to improving the lives of people with hypertrophic cardiomyopathy (HCM). The organization has served the HCM Spectrum Disorder Community since 1996. In this episode, Lisa Salberg, the Founder and CEO of HCMA, talks about the steps she takes to reach patients with misdiagnosis. She also shares how HCMA partnered with Angel Flight East. Tune in for more!

Please visit answersincme.com/PKW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses guideline and treatment updates for the management of hypertrophic cardiomyopathy, and the clinical implications of recent data on novel cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Outline the latest guideline updates for diagnosis and treatment of obstructive HCM; Review strategies to facilitate the early diagnosis of obstructive HCM; and Recognize the clinical significance of the latest data on cardiac myosin inhibitors for the treatment of obstructive HCM.

Commentary by Dr. Valentin Fuster

Tales from the Heart host Lisa Salberg and guests Anna Rodonski, PA-C + Jamie Belden, RN from the Hypertrophic Cardiomyopathy program at Ascension St. Thomas Heart in Nashville, TN. This conversation was recorded Feb. 2, 2024.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Welcome to Tales from the Heart's patient journey segment: Share Your Story. Host Lisa Salberg introduces us to HCMA Project Manager Ross Hadley. Ross not only is on the HCMA staff but he is one of the many faces of Hypertrophic Cardiomyopathy. Listen as he pulls back the curtain and shares his personal journey with HCM. This conversation was recorded Jan. 12, 2024.

Welcome to Tales from the Heart and its new patient journey segment: Share Your Story. Host Lisa Salberg introduces us to HCMA Ambassador Maier Bianchi. Maier is one of the many faces of Hypertrophic Cardiomyopathy. Listen as he pulls back the curtain and shares his personal journey with HCM. This conversation was recorded Jan. 5, 2024.

Tales from the Heart host Lisa Salberg and guest Dr. Matt Martinez discuss what is coming in 2024 for diagnosing + treating Hypertrophic Cardiomyopathy.   This conversation was recorded Jan. 5, 2024.

CardioNerds cofounder Dr. Amit Goyal and cardiology fellows from the Cleveland Clinic (Drs. Alejandro Duran Crane, Gary Parizher, and Simrat Kaur) discuss the following case: A 61-year-old man presented with symptoms of heart failure and left ventricular hypertrophy. He was given a diagnosis of obstructive hypertrophic cardiomyopathy. He eventually underwent septal myectomy, mitral valve replacement, aortic aneurysm repair, and aortic valve replacement with findings of Fabry's disease on surgical pathology. The case discussion focuses on the differential diagnosis for LVH and covers Fabry disease as an HCM mimic. Expert commentary was provided by Dr. Angelika Ewrin. The episode audio was edited by student Dr. Diane Masket. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media - An Unusual Cause of Hypertrophic Cardiomyopathy – Cleveland Clinic Pearls - An Unusual Cause of Hypertrophic Cardiomyopathy – Cleveland Clinic Left ventricular hypertrophy is a cardiac manifestation of several different systemic and cardiac processes, and its etiology should be clarified to avoid missed diagnosis and treatment opportunities. Fabry disease is a rare, X-linked inherited disease that can present cardiac and extra-cardiac manifestations, the former of which include hypertrophic cardiomyopathy, conduction defects, coronary artery disease, conduction abnormalities, arrhythmias, and heart failure.  The diagnosis of Fabry disease includes measurement of alpha-galactosidase enzyme activity as well as genetic testing to evaluate for pathogenic variants or variants of unknown significance in the GLA gene. Family members of patients diagnosed with Fabry disease should be screened based on the inheritance pattern.   Multimodality imaging can be helpful in the diagnosis of Fabry disease. Echocardiography can show left ventricular hypertrophy (LVH), reduced global strain, aortic and mitral valve thickening, and aortic root dilation with associated mild to moderate aortic regurgitation. Cardiac MRI can show hypertrophy of papillary muscles, mid-wall late gadolinium enhancement and low-native T1 signal.   The treatment of Fabry disease involves a multi-disciplinary approach with geneticists, nephrologists, cardiologists, nephrologists, and primary care doctors. Enzyme replacement therapy can delay the progression of cardiac disease.    Show Notes - An Unusual Cause of Hypertrophic Cardiomyopathy – Cleveland Clinic What are the causes of left ventricular hypertrophy? LVH is extremely common. It is present in 15-20% of the general population, and is more common in Black individuals, the elderly, obese or hypertensive individuals, with most cases being secondary to hypertension and aortic valve stenosis. In general terms, it is helpful to divide the causes of LVH into three main groups: high afterload states, obstruction to LV ejection, and intrinsic myocardial problems. Increased afterload states include both primary and secondary hypertension and renal artery stenosis. Mechanical obstruction includes aortic stenosis, subaortic stenosis, and coarctation of the aorta. Lastly, several intrinsic problems of the myocardium can cause LV hypertrophy, such as athletic heart with physiological LVH, hypertrophic cardiomyopathy with or without outflow obstruction, and infiltrative or storage diseases such as cardiac amyloidosis, Fabry's disease, or Danon disease, among others.  How does Fabry disease present? Fabry disease is present in all races and is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene that result in reduced alpha-galactosidase enzyme activity,

This week's routine checkup packs in an inspiring conversation with Lisa Salberg, Founder and CEO of the Hypertrophic Cardiomyopathy Association (HCMA). Lisa's mission to improve the lives of those affected by hypertrophic cardiomyopathy (HCM) stems from her personal experience battling this genetic heart muscle disorder and losing her sister to HCM as well. Despite her own heart transplant in 2017, her commitment remains resolute. In this episode, the fellas discuss screening practices, the signs and symptoms of HCM, and the importance of support for loved ones. Lisa also shares her compelling journey of founding HCMA, a thriving community providing vital resources and life-saving research. Oh and if that's not enough Lisa literally shows the boys her old heart during the interview, which she keeps for educational purposes. Don't miss this powerful conversation that sheds light on HCM, inspires action, and highlights the need for increased awareness and advocacy. Join the post-episode conversation over on Discord! https://discord.gg/expeUDN